Skip to main content
Start triage

Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Need urgent help? Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Roxee Medication Guide

Estriol Tablets

Medication reference facts with explicit FDA-approval, off-label, source-limited, and safety context. Roxee does not sell, prescribe, or dispense medications.

Both Reference complete FDA data linked Rx required Tablet Multiple FDA labelers Official label facts Owner quick guide first
Start Symptom Intake Talk to a Vet / Find a Vet Near You

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Reference facts
Reference refreshed
Aug 6, 2026, 7:47 p.m.

These are the reference facts Roxee uses on browse cards and quick facts.

FDA applications
FDA application data refreshed
Aug 6, 2026, 7:47 p.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports
Safety data refreshed
Aug 6, 2026, 7:49 p.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details
Source timing details
  • Reference facts: Source Roxee | Refreshed Aug 6, 2026, 7:47 PM UTC
    The reference fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Apr 11, 2026, 10:01 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
Illustration placeholder
Estriol Tablets

Estriol Tablets

Drug type: Generic ingredient • Branded profile • FDA branded products available

Both Tablet Rx required 100% reference complete

Species: Both

Manufacturer: Multiple FDA labelers

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Estriol Tablets

For the control of estrogen-responsive urinary incontinence in ovariohysterectomized female dogs. Species commonly shown: Both, Ovariohysterectomized Females.

Generic name
Estriol Tablets
Brand names
Incurin®, AX Pharmaceutical Corp, Incurin
Manufacturer
Multiple FDA labelers
Species
Both, Ovariohysterectomized Females
Dosage forms
Tablet
Prescription
Prescription required
Completeness
100%
Validation
Complete
Brand names
Incurin® AX Pharmaceutical Corp Incurin
Dosage forms
Tablet

Indications / Uses

For the control of estrogen-responsive urinary incontinence in ovariohysterectomized female dogs.

Warnings / Contraindications

Dogs should not receive more than 2 mg Incurin™ Tablets per day (2 tablets). If the dog does not respond to 2 mg of Incurin™ Tablets per day, the diagnosis should be re-assessed. For Oral Use in Dogs Only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

  • Dogs should not receive more than 2 mg Incurin™ Tablets per day (2 tablets). If the dog does not respond to 2 mg of Incurin™ Tablets per day, the diagnosis should be re-assessed. For Oral Use in Dogs Only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Side Effects

Top reported reactions (openFDA): Lack of efficacy - NOS, Swollen vulva, Genital tract licking, Vaginal discharge, Death by euthanasia, Decreased appetite.

FAQ

Both, Ovariohysterectomized Females

Yes. Roxee shows this as prescription-only.

Tablet

Related Conditions

Urinary incontinence (spay incontinence, neurogenic)

Source Transparency

Add to My Pet's Medications

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

For the control of estrogen-responsive urinary incontinence in ovariohysterectomized female dogs.

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

  • Dogs should not receive more than 2 mg Incurin™ Tablets per day (2 tablets)
  • If the dog does not respond to 2 mg of Incurin™ Tablets per day, the diagnosis should be re-assessed
  • For Oral Use in Dogs Only
  • Vomiting (1 reports)
  • wobbly/unsteady walking (1 reports)
  • Loss of appetite (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

Regulatory restrictions are shown in Vet View.

What to tell or ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?

Next actions

Talk to a Vet / Find a Vet Near You Save to pet meds Share page Review report evidence
Research brief

Medication Research Insights

A source-aware map of what to know, what is uncertain, and what to verify with your veterinarian.

Source Backed Signals

What to know

Evidence-backed context Limited

Roxee has limited cited overview evidence for Estriol Tablets; use the official documents and your veterinarian's instructions for product-specific decisions.

Source: openFDA case USA-USFDACVM-2025-US-055529
Safety signal coverage Reported signals

32 tracked reaction signals; 32 reported cases; 28 serious reports; 2 species groups. These are reporting and label-derived signals for interpretation with a veterinarian.

Source: openFDA case USA-USFDACVM-2025-US-055529
Interpretation guardrail Not causation

Adverse-event reports help form a watch list, but they do not prove the medication caused the reaction and they are not a risk ranking between medications.

Evidence tension

Stronger signal Label / review

Official labels, package inserts, and reviewed summaries carry more weight than isolated reports.

Source: openFDA case USA-USFDACVM-2025-US-055529
Weaker signal Reported data

Case reports and openFDA terms are useful for pattern awareness, but they are incomplete, can include multiple exposures, and do not estimate an individual pet's probability of harm.

Reaction signal map

Most reported reactions Top terms

Vomiting (1 reports), Unsteady walking (ataxia) (1 reports), Loss of appetite (1 reports), Growling (1 reports), Genital tract licking (1 reports)

Body systems represented Signal grouping

Digestive (4), Neurologic (1), Behavior (3), Other (24)

Explore supporting adverse reports

Species and breed lens

Species represented in reports Species lens

Dog (30 reports), Cat (2 reports)

Breed metadata in reports Metadata only

Terrier - Bull - American Pit (2), Terrier (unspecified) (1), Japanese Chin (Spaniel) (1), Shepherd Dog - Australian (1). These are report metadata, not proof that a breed is at higher risk.

What your vet may verify

Fit for this patient Vet check

Verify whether Estriol Tablets fits the pet's species, current diagnosis, age, weight, organ status, pregnancy/lactation status, and concurrent medications.

Evidence limitations Evidence review

Separate label-backed warnings from adverse-event reports and owner observations before changing the plan.

What to watch next

Watch list Owner-safe

Dogs should not receive more than 2 mg Incurin™ Tablets per day (2 tablets), If the dog does not respond to 2 mg of Incurin™ Tablets per day, the diagnosis should be re-assessed, For Oral Use in Dogs Only, Vomiting, wobbly/unsteady walking

Call sooner if Escalation

Repeated vomiting or diarrhea. Severe lethargy (hard to wake, very low energy). Collapse or fainting.

Bottom line: Use this Estriol Tablets brief as a structured watch list and source map, not as a reason to start, stop, or change treatment without your veterinarian.
Vet source depth
  1. openFDA case USA-USFDACVM-2025-US-055529 · adverse_reaction · adverse reactions
  2. Contraindication source · fda_animal_drugs · warnings contraindications
  3. FDA application profile · official_label · quick facts
  4. Medication usage source · fda_animal_drugs · quick facts
  5. FOI · document · documents
  6. SPL · document · documents
  7. Structured Product Label · document · documents
  8. Structured Product Label · document · documents

Evidence

Review status / Updated / Sources

Review status: Clinical reviewer not listed

Updated: April 11, 2026, 10:04 AM UTC

Sources:
Safety & side effects

Side effects to monitor:

  • Dogs should not receive more than 2 mg Incurin™ Tablets per day (2 tablets)
  • If the dog does not respond to 2 mg of Incurin™ Tablets per day, the diagnosis should be re-assessed
  • For Oral Use in Dogs Only
  • Vomiting
  • wobbly/unsteady walking

Most reported reactions:

  • Vomiting (1 reports)
  • Unsteady walking (ataxia) (1 reports)
  • Loss of appetite (1 reports)
Explore reported case details

Emergency warning signs:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Vet Fast Scan

Source-backed clinical checkpoints for quick review.

FDA-labeled species
Ovariohysterectomized Females
Indication / use
For the control of estrogen-responsive urinary incontinence in ovariohysterectomized female dogs.
Form / route / dose
Form: Tablet
Route: Oral
Confirm product label and patient-specific plan.
Warnings
  • High: Dogs should not receive more than 2 mg Incurin™ Tablets per day (2 tablets). If the dog does not respond to 2 mg of Inc…
Adverse-event caveat
openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.
Source docs

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: Multiple FDA labelers
Form: Tablet
Identifiers:
NADA: 141325 NDC Package: 0061-4323-01 NDC Package: 62157-460-01 NDC Product: 0061 NDC Product: 62157
Source metadata:

Warnings / Contraindications

Dogs should not receive more than 2 mg Incurin™ Tablets per day (2 tablets). If the dog does not respond to 2 mg of Incurin™ Tablets per day, the diagnosis should be re-assessed. For Oral Use in Dogs Only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

  • High: Dogs should not receive more than 2 mg Incurin™ Tablets per day (2 tablets). If the dog does not respond to 2 mg of Incurin™ Tablets per day, the diagnosis should be re-assessed. For Oral Use in Dogs Only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Reported case explorer

Filter stored openFDA reports by pet and report attributes. Counts describe reports in this data set, not risk.

Clear filters
openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.
Stored reports
11
Matching reports
4
Active filters
2
Selected filters
Reaction: Lethargy (see also Central nervous system depression in Neurological) Clear Body system: Other Clear
Reset
Drill into common report signals
Lethargy (see also Central nervous system depression in Neurological) (4) Not eating (4) Diarrhoea (3) Vomiting (3) Other (11) Digestive (7) Neurologic (4) Behavior (2)
Showing up to 50 matching reports.

USA-USFDACVM-2026-US-011376

Received 2026-03-06 · MSK · MSK

Serious
Species
Dog
Breed
Terrier - Bull - American Pit
Size / weight
50-99 lb (34.654 Kilogram)
Age
4-7 years (4 Year)
Sex
Female Unknown
Region
USA
Reactions
EmesisDiarrhoeaLethargy (see also Central nervous system depression in Neurological)Not eatingWeltTremblingWeight lossElevated symmetrical dimethylarginine (SDMA)Elevated renal parametersHypoproteinaemiaHypoalbuminaemiaLow alanine aminotransferase (ALT)Heart murmurHypertensionChronic kidney diseaseAbnormal ultrasound finding
Body systems
DigestiveNeurologicOther
Outcomes
Ongoing

USA-USFDACVM-2025-US-075175

Received 2025-12-23 · MSK · MSK

Serious
Species
Dog
Breed
Crossbred Canine/dog
Size / weight
50-99 lb (41.277 Kilogram)
Age
8+ years (1 Year)
Sex
Female Unknown
Region
USA
Reactions
Death by euthanasiaAccidental exposureOverdoseVomitingAnorexiaPolydipsiaGeneralised weaknessLethargy (see also Central nervous system depression in Neurological)Dry mucous membraneAtaxiaVomiting foamUnsteady gait
Body systems
OtherDigestiveNeurologic
Outcomes
Euthanized

USA-USFDACVM-2025-US-073880

Received 2025-12-15 · MSK · MSK

Serious
Species
Dog
Breed
['Retriever - Labrador', 'Dog (unknown)']
Size / weight
50-99 lb (28.304 Kilogram)
Age
8+ years (11 Year)
Sex
Female Intact
Region
USA
Reactions
DeathLethargy (see also Central nervous system depression in Neurological)Emesis (multiple)
Body systems
OtherNeurologicDigestive
Outcomes
Died

USA-USFDACVM-2025-US-071646

Received 2025-12-04 · MSK · MSK

Serious
Species
Dog
Breed
['Collie - Border', 'Dog (unknown)']
Size / weight
25-49 lb (20.321 Kilogram)
Age
8+ years (14 Year)
Sex
Female Unknown
Region
USA
Reactions
Lethargy (see also Central nervous system depression in Neurological)GrowlingBiting -aggression (see also Skin and appendages disorders)Not himself/herselfPacingCoughEmesis (multiple)RegurgitationWeaknessAtaxiaNot eatingElevated alanine aminotransferase (ALT)Elevated serum alkaline phosphatase (ALP)Elevated renal parametersHyperphosphataemiaUnable to walk
Body systems
NeurologicOtherBehaviorDigestive
Outcomes
Ongoing

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
28
Species represented
2
Grouped by Body System
Digestive (4) · Vomiting, Loss of appetite, Diarrhea Neurologic (1) · Unsteady walking (ataxia) Behavior (3) · Biting -aggression, Behavioral disorder (unspecified), Anxiety Other (24) · Growling, Glazed eye, Genital tract licking
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Digestive 1 Dog 1
Neurologic 1 Dog 1
Digestive 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1
Other 1 Dog 1

Species coverage: Dog (30) Cat (2)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Digestive Dog Serious - 1
Neurologic Dog Serious - 1
Digestive Dog Serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Digestive Dog Non-serious - 1
Other Dog Serious - 1
Digestive Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Behavior Dog Serious - 1
Behavior Cat Serious - 1
Behavior Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Other Dog Non-serious - 1
Source metadata:

Source Documents

The most useful source links appear first; full previews and metadata stay in the veterinary/professional layer.

Use original documents to confirm product-specific warnings, ingredients, and handling details with your veterinarian.

Incurin® SPL · SPL Incurin SPL SPL · Structured Product Label AX Pharmaceutical Corp SPL SPL · Structured Product Label

Full source previews and metadata remain in the veterinary/professional layer.

Owner handouts

0
No owner handouts linked yet.

Official label / PI

0
No official label or package insert links yet.

SPL

3

FOI

1

Incurin®

SPL · SPL

Open original
FDA Structured Product Label

Incurin®

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Intervet, Inc.
NADA
141-325
Status
RX
Form
Tablet
Route
Oral
Species
Ovariohysterectomized Females
Composition / specifications
1 mg of estriol per tablet

Dogs

Indication
For the control of estrogen-responsive urinary incontinence in ovariohysterectomized female dogs.
Dosage
The dose of Incurin™ Tablets is not dependent upon body weight. All dogs should receive an initial dose of 2 mg Incurin™ Tablets (2 tablets) orally once per day for a minimum of 14 days. After urinary incontinence is controlled, the lowest effective daily dose of Incurin™ Tablets should be determined by decreasing the dose in a step-wise manner from 2 mg once daily (2 tablets) to 1 mg once daily (1 tablet), then 0.5 mg once daily (1/2 tablet) depending upon the response of the individual dog. There should be a minimum of 7 days between each dose adjustment. After the lowest daily dose that controls urinary incontinence is identified, the dose may be decreased further by administering once every two days.
Limitations
Dogs should not receive more than 2 mg Incurin™ Tablets per day (2 tablets). If the dog does not respond to 2 mg of Incurin™ Tablets per day, the diagnosis should be re-assessed. For Oral Use in Dogs Only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Incurin SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for Incurin. Use the source link for the full official labeling record.

AX Pharmaceutical Corp SPL

SPL · Structured Product Label

Open original
FDA Structured Product Label XML for AX Pharmaceutical Corp. Use the source link for the full official labeling record.

UCM265609.pdf

FOI · FOI

Open original
Source metadata:
Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Reference facts: Source Roxee | Refreshed Aug 6, 2026, 7:47 PM UTC
    The reference fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Apr 11, 2026, 10:01 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
Official (FDA)
Identity: Generic ingredient • FDA branded products available
Official FDA brands: AX Pharmaceutical Corp Incurin
Manufacturer mapping: Multiple FDA labelers
Case-reported brands (openFDA): MSK
Catalog species: Both • FDA-labeled species: Ovariohysterectomized Females
Rx/OTC: RX
Form/route: Tablet • Oral
Applications: NADA 141-325
NDC: Packages 0061-4323-01 62157-460-01 • Products 0061 62157
Documents: 1 (FOI: 1) • SPL: 1 • Label highlights • Official documents
Safety (openFDA)
Top reactions: Dog 55 • Cat 0 • View
Case summaries: 11 (showing 8) • View
openFDA reports are unverified and do not prove causation.
Explore
Linked using: Fda_Label (0.95)
Diagnosis Codes

Diagnosis-code mappings are not available for this medication yet.

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • Dogs should not receive more than 2 mg Incurin™ Tablets per day (2 tablets). If the dog does not respond to 2 mg of Incurin™ Tablets per day, the diagnosis should be re-assessed. For Oral Use in Dogs Only. Federal law restricts this drug to use by or on the order of a licensed veterinarian. (Contraindication, High)
Top reaction signals
Vomiting (1) Unsteady walking (ataxia) (1) Loss of appetite (1) Growling (1) Genital tract licking (1) Generalised weakness (1) Fever (1) Elevated symmetrical dimethylarginine (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
NADA: 141325 NDC Package: 0061-4323-01 NDC Package: 62157-460-01 NDC Product: 0061 NDC Product: 62157
Package NDC Product NDC Form / Route Status
0061-4323-01 0061 -
62157-460-01 62157 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

  • Incurin SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • AX Pharmaceutical Corp SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • UCM265609.pdf • FOI summary • Official • Sept. 21, 2020
    FDA FOI summary for application 141325

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 122 Clinical 1 Manufacturer 0 Marketing 0
Current Field Facts
  • side_effects: Top reported reactions (openFDA): Lack of efficacy - NOS, Swollen vulva, Genital tract licking, Vaginal discharge, Death by euthanasia, Decreased appetite. (Clinical, 2026-04-11)
  • contraindications: Dogs should not receive more than 2 mg Incurin™ Tablets per day (2 tablets). If the dog does not respond to 2 mg of Incurin™ Tablets per day, the diagnosis sho… (Official, 2026-04-12)
  • contraindications: Dogs should not receive more than 2 mg Incurin™ Tablets per day (2 tablets). If the dog does not respond to 2 mg of Incurin™ Tablets per day, the diagnosis sho… (Official, 2026-04-11)
  • indications: For the control of estrogen-responsive urinary incontinence in ovariohysterectomized female dogs. (Official, 2026-08-06)
  • indications: For the control of estrogen-responsive urinary incontinence in ovariohysterectomized female dogs. (Official, 2026-08-05)
  • indications: For the control of estrogen-responsive urinary incontinence in ovariohysterectomized female dogs. (Official, 2026-08-04)
  • indications: For the control of estrogen-responsive urinary incontinence in ovariohysterectomized female dogs. (Official, 2026-08-03)
  • indications: For the control of estrogen-responsive urinary incontinence in ovariohysterectomized female dogs. (Official, 2026-08-02)
  • indications: For the control of estrogen-responsive urinary incontinence in ovariohysterectomized female dogs. (Official, 2026-08-01)
  • indications: For the control of estrogen-responsive urinary incontinence in ovariohysterectomized female dogs. (Official, 2026-07-31)
  • indications: For the control of estrogen-responsive urinary incontinence in ovariohysterectomized female dogs. (Official, 2026-07-30)
  • indications: For the control of estrogen-responsive urinary incontinence in ovariohysterectomized female dogs. (Official, 2026-07-29)
  • indications: For the control of estrogen-responsive urinary incontinence in ovariohysterectomized female dogs. (Official, 2026-07-28)
  • indications: For the control of estrogen-responsive urinary incontinence in ovariohysterectomized female dogs. (Official, 2026-07-27)
  • indications: For the control of estrogen-responsive urinary incontinence in ovariohysterectomized female dogs. (Official, 2026-07-26)
  • indications: For the control of estrogen-responsive urinary incontinence in ovariohysterectomized female dogs. (Official, 2026-07-25)
  • indications: For the control of estrogen-responsive urinary incontinence in ovariohysterectomized female dogs. (Official, 2026-07-25)
  • indications: For the control of estrogen-responsive urinary incontinence in ovariohysterectomized female dogs. (Official, 2026-07-22)
  • indications: For the control of estrogen-responsive urinary incontinence in ovariohysterectomized female dogs. (Official, 2026-07-22)
  • indications: For the control of estrogen-responsive urinary incontinence in ovariohysterectomized female dogs. (Official, 2026-07-22)
Recent Revisions
  • side_effects updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
Incurin®
RX
estriol
Tablet • Oral
Label highlights
Official documents
Intervet, Inc. NADA 141-325 Approved Sep 21, 2020

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Ovariohysterectomized Females
Composition / specifications
1 mg of estriol per tablet
Dogs
Indication
For the control of estrogen-responsive urinary incontinence in ovariohysterectomized female dogs.
Dosage
The dose of Incurin™ Tablets is not dependent upon body weight. All dogs should receive an initial dose of 2 mg Incurin™ Tablets (2 tablets) orally once per day for a minimum of 14 days. After urinary incontinence is controlled, the lowest effective daily dose of Incurin™ Tablets should be determined by decreasing the dose in a step-wise manner from 2 mg once daily (2 tablets) to 1 mg once daily (1 tablet), then 0.5 mg once daily (1/2 tablet) depending upon the response of the individual dog. There should be a minimum of 7 days between each dose adjustment. After the lowest daily dose that controls urinary incontinence is identified, the dose may be decreased further by administering once every two days.
Limitations
Dogs should not receive more than 2 mg Incurin™ Tablets per day (2 tablets). If the dog does not respond to 2 mg of Incurin™ Tablets per day, the diagnosis should be re-assessed. For Oral Use in Dogs Only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Usage

For the control of estrogen-responsive urinary incontinence in ovariohysterectomized female dogs.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Dogs should not receive more than 2 mg Incurin™ Tablets per day (2 tablets). If the dog does not respond to 2 mg of Incurin™ Tablets per day, the diagnosis should be re-assessed. For Oral Use in Dogs Only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive
Vomiting (1) • Dog Loss of appetite (1) • Dog Diarrhea (1) • Dog Decreased appetite (1) • Dog

Showing top 5 for Digestive.

Neurologic
Unsteady walking (1) • Dog

Showing top 5 for Neurologic.

Behavior
Biting -aggression (1) • Dog Behavioral disorder (1) • Cat Anxiety (1) • Dog

Showing top 5 for Behavior.

Other
Growling (1) • Dog Glazed eye (1) • Dog Genital tract licking (1) • Dog Generalised weakness (1) • Dog Fever (1) • Dog
Show more (19)
Elevated symmetrical dimethylarginine (1) • Dog Elevated serum alkaline phosphatase (1) • Dog Elevated renal parameters (1) • Dog Elevated alanine aminotransferase (1) • Dog Dry mucous membrane (1) • Dog Distension of abdomen (1) • Cat Dehydration (1) • Dog Death by euthanasia (1) • Dog Death (1) • Dog Cough (1) • Dog Chronic kidney disease (1) • Dog Cervical pain (1) • Dog Bone and joint disorder NOS (1) • Dog Anal sac disorder (1) • Dog Accidental exposure (1) • Dog Abnormal ultrasound finding (1) • Dog Abnormal radiograph finding (1) • Dog Abnormal oestrus NOS (1) • Dog Abnormal cytology (1) • Dog

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Terrier (unspecified), Female, 15 year, 4.264 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Vomiting, Diarrhea, Not eating, Medication error NOS • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2026-US-013433
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 15.00 Year
  • Weight: 4.264 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Vomiting Diarrhea Not eating Medication error NOS
Outcomes: Ongoing

Dog, Japanese Chin (Spaniel), Female, 11 year, 1.905 kilogram • Drug: MSK, Tablet, Unknown • Reactions: Loss of hearing • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2026-US-014535
  • Serious AE: Yes
  • Treated For AE: No
  • Sex: Female
  • Age: 11.00 Year
  • Weight: 1.905 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Tablet
Reactions Reported:
Loss of hearing
Outcomes: Outcome Unknown

Dog, Shepherd Dog - Australian, Female, 9.9 year, 19.5 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Whining, Anxiety, Itching, Urine leakage, Lack of efficacy - NOS • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2026-US-012722
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 9.90 Year
  • Weight: 19.500 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Whining Anxiety Itching Urine leakage Lack of efficacy - NOS
Outcomes: Outcome Unknown

Dog, Shepherd Dog - German, Female, 5 year, 38.918 kilogram • Drug: MSK, Tablet, Unknown • Reactions: Swelling NOS, Lameness, Bone and joint disorder NOS, Abnormal radiograph finding • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2026-US-013136
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 5.00 Year
  • Weight: 38.918 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Tablet
Reactions Reported:
Swelling NOS Lameness Bone and joint disorder NOS Abnormal radiograph finding
Outcomes: Ongoing

Dog, Terrier - Bull - American Pit, Female, 4 year, 34.654 kilogram • Drug: MSK, Unassigned, Oral • Reactions: Vomiting, Diarrhea, Tiredness (lethargy), Not eating, Welt… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2026-US-011376
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 4.00 Year
  • Weight: 34.654 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Oral
  • Form: Unassigned
Reactions Reported:
Vomiting Diarrhea Tiredness (lethargy) Not eating Welt Trembling Weight loss Elevated symmetrical dimethylarginine Elevated renal parameters Hypoproteinaemia Hypoalbuminaemia Low alanine aminotransferase Heart murmur Hypertension Chronic kidney disease Abnormal ultrasound finding
Outcomes: Ongoing

Dog, Terrier - Bull - American Pit, Female, 3 year, 17.463 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Vomiting, Diarrhea, Intentional misuse • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2025-US-075432
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 3.00 Year
  • Weight: 17.463 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Vomiting Diarrhea Intentional misuse
Outcomes: Recovered/Normal

Dog, Crossbred Canine/dog, Female, 10 year, 41.277 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Death by euthanasia, Accidental exposure, Overdose, Vomiting, Loss of appetite… • Outcome: Euthanized

  • Report ID: USA-USFDACVM-2025-US-075175
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 10.00 Year
  • Weight: 41.277 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Death by euthanasia Accidental exposure Overdose Vomiting Loss of appetite Polydipsia Generalised weakness Tiredness (lethargy) Dry mucous membrane Unsteady walking (ataxia) Vomiting foam Unsteady gait
Outcomes: Euthanized

Dog, ['Crossbred Canine/dog', 'Chihuahua'], Female, 10 year, 6.36 kilogram • Drug: MSK, Tablet, Unknown, Dose: 0.50 Milligram per animal, Frequency: 24 per hour • Reactions: Dehydration, Fever, Decreased appetite • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-075314
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 10.00 Year
  • Weight: 6.360 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Tablet
  • Dose: 0.50 Milligram per animal
  • Frequency: 24 per hour
Reactions Reported:
Dehydration Fever Decreased appetite
Outcomes: Ongoing

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.